UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000032705
Receipt number R000037294
Scientific Title Prospective, randomized, open-label, clinical trial comparing the effects of dapagliflozin and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients
Date of disclosure of the study information 2018/05/24
Last modified on 2020/05/25 17:57:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Prospective, randomized, open-label, clinical trial comparing the effects of dapagliflozin and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients

Acronym

Effects of dapagliflozin and sitagliptin on endothelial fiction

Scientific Title

Prospective, randomized, open-label, clinical trial comparing the effects of dapagliflozin and sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients

Scientific Title:Acronym

Effects of dapagliflozin and sitagliptin on endothelial fiction

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Comparison of dapagliflozin versus sitagliptin on glucose/lipids metabolism and endothelial function in diabetic patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Hemoglobin A1C levels, glycoalbumin levels, blood glucose/lipids levels, and flow-mediated vasodilation in forearm
Twelve weeks after administration

Key secondary outcomes

Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria)
Twelve weeks after administration


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Administration of dapagliflozin first, then change to sitagliptin (for 12 weeks each)

Interventions/Control_2

Administration of dapagliflozin first, then change to exenatide (for 12 weeks each)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Diabetic patients whose HbA1c levels are greater than 7, despite medical therapy including life style change/medications for at least 8 weeks
2) 20 years of age or older and 75 years of age or younger.
3) Female or Male
4) Outpatients
5) Subjects who gave written informed consent

Key exclusion criteria

1) Allergy against dapagliflozin/sitagliptin
2) Type I diabetes
3) Secondary diabetes
4) Poor-controlled diabetes (HbA1c>10.0 %)
5) Subjects who takes GLP-1 receptor agonist or DPP4 inhibitor.
6)History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
7) Either level of aspartate aminotransaminase or alanine aminotransferase exceed three-fold of the normal limits
8) renal insufficiency: serum creatinine>1.3 (male)>1.2(female)
9) Symptomatic (NYHA III or IV) congestive heart failure
10) Malignancies or other diseases with poor prognosis
11) Pregnant
12) Subjects whose doctor in charge do not agree to join the trial

Target sample size

33


Research contact person

Name of lead principal investigator

1st name Makoto
Middle name
Last name Ayaori

Organization

Tokorozawa Heart Center

Division name

Shintokoekimae Clinic

Zip code

359-1111

Address

1-4-1-101 Midoricho, Tokorozawa, Japan 359-1111

TEL

0429291801

Email

ayaori@ba2.so-net.ne.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Ayaori

Organization

Tokorozawa Heart Center

Division name

Shintokoekimae Clinic

Zip code

359-1111

Address

1-4-1-101 Midoricho, Tokorozawa, Japan 359-1111

TEL

0429291801

Homepage URL


Email

ayaori@ba2.so-net.ne.jp


Sponsor or person

Institute

Tokorozawa Heart Center

Institute

Department

Personal name



Funding Source

Organization

Foundation for Promotion of Defense Medicine

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tokorozawa Heart Center IRB

Address

2-61-11 Kamiarai, Tokorozawa, Saitama, JAPAN 359-1142

Tel

04-2940-8611

Email

cs.thc@oukai.or.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 05 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

30

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2018 Year 05 Month 16 Day

Date of IRB

2018 Year 04 Month 19 Day

Anticipated trial start date

2018 Year 05 Month 24 Day

Last follow-up date

2021 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2018 Year 05 Month 24 Day

Last modified on

2020 Year 05 Month 25 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000037294


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name